On September 23, 2019 4SC AG (4SC, FSE Prime Standard: VSC) reported that two posters on clinical studies combining domatinostat and anti-PD-(L)1 checkpoint inhibitor will be presented at the European Society of Medical Oncology (ESMO) (Free ESMO Whitepaper) Congress being held on 27 September to 1 October 2019 in Barcelona, Spain (Press release, 4SC, SEP 23, 2019, View Source [SID1234539707]). The posters will be available on 4SC’s website after the presentation.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Poster presentations at the ESMO (Free ESMO Whitepaper) Congress 2019

Poster EMERGE: Epigenetic Modulation of the Immune Response in Gastrointestinal cancers (Trial in progress)
Session Poster Display session 2 (ID 211)
Time Sunday, 29 September 2019, 12:00 – 13:00 CEST
Location Poster Area (Hall 4)
Poster Phase Ib/II Study (SENSITIZE) assessing safety, pharmacokinetics (PK), pharmacodynamics (PD), and clinical outcome of domatinostat in combination with pembrolizumab in patients with advanced melanoma refractory/non-responding to prior checkpoint inhibitor therapy
Session Poster Display session 3 (ID 212)
Time Monday, 30 September 2019, 12:00 – 13:00 CEST
Location Poster Area (Hall 4)
Related articles
11 July 2019, 4SC AG: Positive safety review of Phase Ib/II SENSITIZE study of domatinostat + pembrolizumab in melanoma

8 April 2019, 4SC AG: Domatinostat’s mode of action in Merkel cell carcinoma

6 February 2019, First patient enrolled in Phase II study EMERGE of domatinostat (4SC-202) in gastrointestinal cancer